{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:46:38Z","timestamp":1790531198421,"version":"4.1.0"},"reference-count":97,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,7,17]]},"DOI":"10.3233\/jad-170184","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T10:49:02Z","timestamp":1498560542000},"page":"763-783","source":"Crossref","is-referenced-by-count":45,"title":["Four Decades of Research in Alzheimer\u2019s Disease (1975\u20132014): A Bibliometric and Scientometric Analysis"],"prefix":"10.1177","volume":"59","author":[{"given":"Alberto","family":"Serrano-Pozo","sequence":"first","affiliation":[{"name":"Department of Neurology, University of IowaHospitals and Clinics, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina M.","family":"Aldridge","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of IowaHospitals and Clinics, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of IowaHospitals and Clinics, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-170184_ref1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1976.00500040001001","article-title":"Editorial: The prevalence and malignancy of Alzheimer disease. A major killer","volume":"33","author":"Katzman","year":"1976","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-170184_ref2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","article-title":"2015 Alzheimer\u2019s disease facts andfigures","volume":"11","author":"Alzheimer\u2019s Association","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170184_ref4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-2012-111943","article-title":"The 2008-2012 French Alzheimer plan: Description of the national Alzheimer information system","volume":"29","author":"Le Duff","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-170184_ref5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jalz.2012.04.004","article-title":"The draft \u201cNational Plan\u201d to address Alzheimer\u2019s disease - National Alzheimer\u2019s Project Act (NAPA)","volume":"8","author":"Khachaturian","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170184_ref6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458514540357","article-title":"Bibliometric profile of the global scientific research on multiplesclerosis (2003-2012)","volume":"21","author":"Aleixandre-Benavent","year":"2015","journal-title":"Mult Scler Houndmills BasingstokeEngl"},{"key":"10.3233\/JAD-170184_ref7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neulet.2008.06.044","article-title":"Bibliometric analysis on global Parkinson\u2019s disease research trends during 1991-2006","volume":"441","author":"Li","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-170184_ref8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3233\/JAD-150275","article-title":"Telling the story of frontotemporal dementia by bibliometric analysis","volume":"48","author":"Guido","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-170184_ref9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jns.2015.08.001","article-title":"Evolving trends in cerebral amyloid angiopathy research themes: Insights from medical subject heading analysis","volume":"357","author":"Charidimou","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-170184_ref10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/jnnp-2015-310690","article-title":"Mapping the landscape of cerebral amyloid angiopathy research: An informetric analysis perspective","volume":"87","author":"Charidimou","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-170184_ref11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jama.1994.03510380059038","article-title":"Understanding and using the medical subject headings (MeSH) vocabulary to perform literature searches","volume":"271","author":"Lowe","year":"1994","journal-title":"JAMA"},{"key":"10.3233\/JAD-170184_ref12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jamia.2001.0080317","article-title":"Medical subject headings used to search the biomedical literature","volume":"8","author":"Coletti","year":"2001","journal-title":"J Am Med Inform Assoc"},{"key":"10.3233\/JAD-170184_ref13","first-page":"349","article-title":"Comparison of Medical Subject Headings and text-word searches in MEDLINE to retrieve studies on sleep in healthy individuals","volume":"92","author":"Jenuwine","year":"2004","journal-title":"J Med Libr Assoc"},{"key":"10.3233\/JAD-170184_ref14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.mlg.0000195371.72887.a2","article-title":"Searching the literature using medical subject headings versus text word with PubMed","volume":"116","author":"Chang","year":"2006","journal-title":"Laryngoscope"},{"key":"10.3233\/JAD-170184_ref15","doi-asserted-by":"crossref","first-page":"16569","DOI":"10.1073\/pnas.0507655102","article-title":"An index to quantify an individual\u2019s scientific research output","volume":"102","author":"Hirsch","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-170184_ref16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.24258","article-title":"Weighed and measured","volume":"76","author":"Saper","year":"2014","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170184_ref17","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3171\/2013.11.JNS131708","article-title":"An analysis of publication productivity for 1225 neurosurgeons and 99 departments in the United States","volume":"120","author":"Khan","year":"2014","journal-title":"J Neurosurg"},{"key":"10.3233\/JAD-170184_ref18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11192-006-0146-5","article-title":"An extension of the Hirsch index: Indexing scientific topics and compounds","volume":"69","author":"Banks","year":"2006","journal-title":"Scientometrics"},{"key":"10.3233\/JAD-170184_ref19","doi-asserted-by":"crossref","first-page":"16569","DOI":"10.1073\/pnas.0507655102","article-title":"An index to quantify an individual\u2019s scientific research output","volume":"102","author":"Hirsch","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-170184_ref20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.24258","article-title":"Weighed and measured","volume":"76","author":"Saper","year":"2014","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170184_ref21","doi-asserted-by":"crossref","first-page":"e49476","DOI":"10.1371\/journal.pone.0049476","article-title":"The impact of article length on the number of futurecitations: A bibliometric analysis of general medicine journals","volume":"8","author":"Falagas","year":"2013","journal-title":"PLoS One"},{"key":"10.3233\/JAD-170184_ref22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaneurol.2013.6225","article-title":"The growth and impact of Alzheimer disease centers as measured by social network analysis","volume":"71","author":"Hughes","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-170184_ref23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11192-010-0306-5","article-title":"Detecting h-index manipulation through self-citation analysis","volume":"87","author":"Bartneck","year":"2011","journal-title":"Scientometrics"},{"key":"10.3233\/JAD-170184_ref24","doi-asserted-by":"crossref","first-page":"e0161021","DOI":"10.1371\/journal.pone.0161021","article-title":"A large-scale analysis of impact factorbiased journal self-citations","volume":"11","author":"Chorus","year":"2016","journal-title":"PLoS One"},{"key":"10.3233\/JAD-170184_ref25","doi-asserted-by":"crossref","first-page":"e0153730","DOI":"10.1371\/journal.pone.0153730","article-title":"From excessive journal self-cites to citationstacking: Analysis of journal self-citation kinetics in search forjournals, which boost their scientometric indicators","volume":"11","author":"Heneberg","year":"2016","journal-title":"PLoS One"},{"key":"10.3233\/JAD-170184_ref26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archneur.57.1.94","article-title":"Donepezil therapy in clinical practice: A randomized crossover study","volume":"57","author":"Greenberg","year":"2000","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-170184_ref27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000017259","article-title":"Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer\u2019s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group","volume":"11","author":"Homma","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-170184_ref28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"Donepezil MSAD Study Investigators Group, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer\u2019s disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref30","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref31","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: Multicentre randomised controlled trial","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"10.3233\/JAD-170184_ref33","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer\u2019s disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-170184_ref34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: A randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.3233\/JAD-170184_ref35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archneur.61.2.252","article-title":"The cognitive benefits of galantamine are sustained for at least 36 months: A long-term extension trial","volume":"61","author":"Raskind","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-170184_ref36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","article-title":"A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer\u2019s disease","volume":"44","author":"Farlow","year":"2000","journal-title":"Eur Neurol"},{"key":"10.3233\/JAD-170184_ref37","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer\u2019s disease: Randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ"},{"key":"10.3233\/JAD-170184_ref38","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-170184_ref39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"10.3233\/JAD-170184_ref40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref41","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","article-title":"Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein","volume":"373","author":"Games","year":"1995","journal-title":"Nature"},{"key":"10.3233\/JAD-170184_ref43","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1073\/pnas.92.12.5341","article-title":"Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein","volume":"92","author":"Moran","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-170184_ref44","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0896-6273(00)80974-5","article-title":"Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins","volume":"19","author":"Borchelt","year":"1997","journal-title":"Neuron"},{"key":"10.3233\/JAD-170184_ref45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nm0198-097","article-title":"Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes","volume":"4","author":"Holcomb","year":"1998","journal-title":"Nat Med"},{"key":"10.3233\/JAD-170184_ref46","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archneur.1985.04060100083029","article-title":"Diagnosis of Alzheimer\u2019s disease","volume":"42","author":"Khachaturian","year":"1985","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-170184_ref47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol (Berl.)"},{"key":"10.3233\/JAD-170184_ref49","unstructured":"(1997) Consensus recommendations for the postmortem diagnosis of Alzheimer\u2019s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer\u2019s Disease. Neurobiol Aging 18, S1\u20132."},{"key":"10.3233\/JAD-170184_ref50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170184_ref51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: A practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol (Berl.)"},{"key":"10.3233\/JAD-170184_ref52","first-page":"270","article-title":"The National Alzheimer\u2019s Coordinating Center (NACC) Database: An Alzheimer disease database","volume":"18","author":"Beekly","year":"2004","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-170184_ref53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/01.jnen.0000229986.17548.27","article-title":"Interlaboratory comparison ofassessments of Alzheimer disease-related lesions: A study of theBrainNet Europe Consortium","volume":"65","author":"Alafuzoff","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-170184_ref54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with PittsburghCompound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170184_ref55","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.3233\/JAD-170184_ref56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170184_ref57","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: A multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170184_ref58","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"10.3233\/JAD-170184_ref59","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain","volume":"89","author":"Sch\u00f6ll","year":"2016","journal-title":"Neuron"},{"key":"10.3233\/JAD-170184_ref60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel taupositron emission tomography tracer [F-18]-AV-1451 (T807) onpostmortem brain tissue","volume":"78","author":"Marqui\u00e9","year":"2015","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170184_ref61","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(01)05625-2","article-title":"In-vivo measurement of activated microglia in dementia","volume":"358","author":"Cagnin","year":"2001","journal-title":"Lancet"},{"key":"10.3233\/JAD-170184_ref62","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/brain\/awt145","article-title":"In vivo radioligand binding to translocator protein correlates with severity of Alzheimer\u2019s disease","volume":"136","author":"Kreisl","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JAD-170184_ref63","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med"},{"key":"10.3233\/JAD-170184_ref64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","article-title":"Ways toward an early diagnosis in Alzheimer\u2019s disease: The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","volume":"1","author":"Mueller","year":"2005","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170184_ref65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCGENETICS.108.829747","article-title":"Cohorts for Heart and Aging Research inGenomic Epidemiology (CHARGE) Consortium: Design of prospectivemeta-analyses of genome-wide association studies from 5 cohorts","volume":"2","author":"Psaty","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.3233\/JAD-170184_ref66","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046individuals identifies 11 new susceptibility loci for Alzheimer\u2019sdisease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-170184_ref67","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3233\/JAD-170184_ref68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer\u2019s disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron"},{"key":"10.3233\/JAD-170184_ref69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.3233\/JAD-170184_ref70","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","article-title":"Microtubule-associated protein tau. A component of Alzheimer paired helical filaments","volume":"261","author":"Grundke-Iqbal","year":"1986","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-170184_ref71","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.83.11.4040","article-title":"Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau)","volume":"83","author":"Wood","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-170184_ref72","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/oxfordjournals.jbchem.a135662","article-title":"Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer\u2019s disease","volume":"99","author":"Ihara","year":"1986","journal-title":"J Biochem (Tokyo)"},{"key":"10.3233\/JAD-170184_ref73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ana.10281","article-title":"Tauists, Baptists, Syners, Apostates, and new data","volume":"52","author":"Trojanowski","year":"2002","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170184_ref74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0166-2236(00)02031-2","article-title":"Alzheimer\u2019s disease-do tauists and baptists finally shake hands?","volume":"25","author":"Mudher","year":"2002","journal-title":"Trends Neurosci"},{"key":"10.3233\/JAD-170184_ref75","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: An appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.3233\/JAD-170184_ref76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","article-title":"A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease","volume":"76","author":"Karran","year":"2014","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-170184_ref77","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.3233\/JAD-170184_ref78","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","article-title":"Apolipoprotein E in sporadic Alzheimer\u2019s disease: Allelic variation and receptor interactions","volume":"11","author":"Rebeck","year":"1993","journal-title":"Neuron"},{"key":"10.3233\/JAD-170184_ref79","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wideassociation study identifies variants at CLU and CR1 associatedwith Alzheimer\u2019s disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-170184_ref80","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","article-title":"Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP areassociated with Alzheimer\u2019s disease","volume":"43","author":"Hollingworth","year":"2011","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-170184_ref81","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer\u2019s disease","volume":"43","author":"Naj","year":"2011","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-170184_ref82","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer\u2019s disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-170184_ref83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-170184_ref84","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","article-title":"The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence","volume":"10","author":"Barnes","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170184_ref85","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","article-title":"Potential for primary prevention of Alzheimer\u2019s disease: An analysis of population-based data","volume":"13","author":"Norton","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170184_ref86","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","article-title":"Nonsteroidal antiinflammatory drugs and the risk of Alzheimer\u2019s disease","volume":"345","author":"in t\u2019 Veld","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-170184_ref87","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1212\/WNL.48.3.626","article-title":"Risk of Alzheimer\u2019s disease and duration of NSAID use","volume":"48","author":"Stewart","year":"1997","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref88","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1212\/WNL.54.11.2066","article-title":"Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study","volume":"54","author":"Anthony","year":"2000","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref89","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","article-title":"Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors","volume":"57","author":"Wolozin","year":"2000","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-170184_ref90","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"key":"10.3233\/JAD-170184_ref91","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: No effect on Alzheimer\u2019s disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref92","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.3233\/JAD-170184_ref93","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"10.3233\/JAD-170184_ref94","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref95","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-170184_ref96","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JAD-170184_ref97","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/WAD.0b013e3181611024","article-title":"A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: The TRIMCI study","volume":"22","author":"G\u00f3mez-Isla","year":"2008","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-170184_ref98","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","article-title":"Cognitive function over time in the Alzheimer\u2019s DiseaseAnti-inflammatory Prevention Trial (ADAPT): Results of arandomized, controlled trial of naproxen and celecoxib","volume":"65","author":"Martin","year":"2008","journal-title":"Arch Neurol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-170184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:09Z","timestamp":1777370649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-170184"}},"subtitle":[],"editor":[{"given":"Aaron","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":97,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-170184","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}